{"nctId":"NCT00531479","briefTitle":"Anidulafungin Plus Voriconazole Versus Voriconazole For The Treatment Of Invasive Aspergillosis","startDateStruct":{"date":"2008-07"},"conditions":["Aspergillosis"],"count":459,"armGroups":[{"label":"Voriconazole","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: voriconazole"]},{"label":"Voriconazole and Anidulafungin","type":"EXPERIMENTAL","interventionNames":["Drug: anidulafungin","Drug: voriconazole"]}],"interventions":[{"name":"voriconazole","otherNames":["Vfend"]},{"name":"anidulafungin","otherNames":["Eraxis"]},{"name":"voriconazole","otherNames":["Vfend"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Immunocompromised state due to either 1. receipt of hematopoeitic stem cell transplantation or 2. hematologic malignancy;\n* Diagnosis of possible, probable, or proven invasive aspergillosis.\n\nExclusion Criteria:\n\n* Patients with aspergilloma or chronic aspergillosis\n* Receipt of 4 or more days of systemic antifungal treatment for the current episode of invasive aspergillosis\n* Anticipated survival of less than 5 days or Karnofsky score \\<=20","healthyVolunteers":false,"sex":"ALL","minimumAge":"16 Years","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"All-cause Mortality at Week 6 in Participants With Proven or Probable Invasive Aspergillosis","description":"Number of deaths measured 6 weeks after start of treatment. Time to death defined as date of death minus first treatment date + 1.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"26","spread":null},{"groupId":"OG001","value":"39","spread":null}]}]}]},{"type":"SECONDARY","title":"Global Response at Week 6","description":"Number of participants with a successful response (complete or partial global response). Complete response = resolution of all clinical signs and symptoms and \\>90% of lesions due to IA that were visible on radiologic studies at baseline (BL); partial response = clinical improvement and \\>50% improvement in radiological findings present at BL.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"44","spread":null},{"groupId":"OG001","value":"61","spread":null}]}]}]},{"type":"SECONDARY","title":"All-cause Mortality at Week 6 in Participants With Possible, Probable, or Proven Invasive Aspergillosis (IA)","description":"Number of deaths due to any cause measured 6 weeks after start of treatment. Time to death defined as date of death minus first treatment date + 1.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"44","spread":null},{"groupId":"OG001","value":"47","spread":null}]}]}]},{"type":"SECONDARY","title":"All-cause Mortality at Week 12 in Participants With Probable or Proven Invasive Aspergillosis (IA)","description":"Number of deaths due to any cause measured 12 weeks after start of treatment. Time to death defined as date of death minus first treatment date + 1.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"39","spread":null},{"groupId":"OG001","value":"55","spread":null}]}]}]},{"type":"SECONDARY","title":"Mortality Due to Invasive Aspergillosis (IA) at Week 6 in Participants With Probable or Proven IA","description":"Number of deaths due to Invasive Aspergillosis measured 6 weeks after start of treatment. Time to death defined as date of death minus first treatment date + 1.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"23","spread":null},{"groupId":"OG001","value":"33","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to Death: All-Cause Mortality","description":"Survival time from start of treatment. Time to death defined as date of death due to any cause minus first treatment date + 1.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"30.0","spread":null},{"groupId":"OG001","value":"30.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to Death Due to Invasive Aspergillosis (IA)","description":"Survival time from start of treatment. Time to death defined as date of death due to IA minus first treatment date + 1.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14.0","spread":null},{"groupId":"OG001","value":"18.5","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":115,"n":228},"commonTop":["Nausea","Diarrhoea","Pyrexia","Oedema peripheral","Hypokalaemia"]}}}